Literature DB >> 19177550

Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome.

Marietta E Kovacs1, Janos Papp, Zoltan Szentirmay, Szabolcs Otto, Edith Olah.   

Abstract

Several different genetic alterations in the etiology of Lynch syndrome (hereditary nonpolyposis colorectal cancer [HNPCC]) are known, mostly point mutations and genomic rearrangements in 1 of at least 3 mismatch-repair (MMR) genes. However, no susceptibility factor has yet been identified in a significant part (30-50%) of clinicopathologically well-defined HNPCC families, suggesting the presence of other predisposing mechanisms. In a set of probands from 27 Lynch syndrome families who lacked evidence of a germline mutation in either the MSH2 or MLH1 gene, we performed genomic deletion screening with the use of multiplex ligation-dependent probe amplification (MLPA) and sequencing. We used immunohistochemistry (IHC) and microsatellite instability (MSI) analyses on samples of the probands of all families. Comparative analysis of mRNA transcripts was performed on blood leukocyte-derived samples from mutation carriers and noncarrier controls. We report that large germline deletions encompassing the last exons of the TACSTD1 gene, upstream of MSH2, cosegregate with the HNPCC phenotype in 19% (5/27) of families tested. The tumors of the carriers show high-level MSI and MSH2 protein loss. We show that these deletions, by removing the transcriptional termination sequences of the upstream gene, give rise to multiple TACSTD1/MSH2 fusion transcripts. Our results provide evidence that deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome. Thus, analysis of the 3' region of the TACSTD1 gene should be included in the routine mutation screening protocols for HNPCC. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19177550     DOI: 10.1002/humu.20942

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  62 in total

Review 1.  Lynch syndrome diagnostics: decision-making process for germ-line testing.

Authors:  E Lastra; M García-González; B Llorente; C Bernuy; M J Barrio; L Pérez-Cabornero; M Durán; C García-Girón
Journal:  Clin Transl Oncol       Date:  2012-04       Impact factor: 3.405

2.  EPCAM germ line deletions as causes of Lynch syndrome in Spanish patients.

Authors:  Carla Guarinos; Adela Castillejo; Víctor-Manuel Barberá; Lucía Pérez-Carbonell; Ana-Beatriz Sánchez-Heras; Angel Segura; Carmen Guillén-Ponce; Ana Martínez-Cantó; María-Isabel Castillejo; Cecilia-Magdalena Egoavil; Rodrigo Jover; Artemio Payá; Cristina Alenda; José-Luís Soto
Journal:  J Mol Diagn       Date:  2010-09-23       Impact factor: 5.568

3.  The analysis of a large Danish family supports the presence of a susceptibility locus for adenoma and colorectal cancer on chromosome 11q24.

Authors:  Laura Aviaja Rudkjøbing; Hans Eiberg; Hanne Birte Mikkelsen; Marie Louise Mølgaard Binderup; Marie Luise Bisgaard
Journal:  Fam Cancer       Date:  2015-09       Impact factor: 2.375

4.  Multivariate analysis of MLH1 c.1664T>C (p.Leu555Pro) mismatch repair gene variant demonstrates its pathogenicity.

Authors:  M P Farrell; D J Hughes; M Drost; A J Wallace; R J Cummins; T A Fletcher; M A Meany; E W Kay; N de Wind; D G Power; E J Andrews; A J Green; D J Gallagher
Journal:  Fam Cancer       Date:  2013-12       Impact factor: 2.375

Review 5.  History, genetics, and strategies for cancer prevention in Lynch syndrome.

Authors:  Fay Kastrinos; Elena M Stoffel
Journal:  Clin Gastroenterol Hepatol       Date:  2013-07-23       Impact factor: 11.382

Review 6.  Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer.

Authors:  Jung Ho Kim; Gyeong Hoon Kang
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

7.  Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated Lynch syndrome cases.

Authors:  Kandelaria Rumilla; Karen V Schowalter; Noralane M Lindor; Brittany C Thomas; Kara A Mensink; Steven Gallinger; Spring Holter; Polly A Newcomb; John D Potter; Mark A Jenkins; John L Hopper; Tiffany I Long; Daniel J Weisenberger; Robert W Haile; Graham Casey; Peter W Laird; Loic Le Marchand; Stephen N Thibodeau
Journal:  J Mol Diagn       Date:  2010-12-23       Impact factor: 5.568

8.  Hereditary gastrointestinal cancer syndromes.

Authors:  Henry T Lynch; Jane F Lynch; Trudy G Shaw
Journal:  Gastrointest Cancer Res       Date:  2011-07

9.  Comparative effectiveness of next generation genomic sequencing for disease diagnosis: design of a randomized controlled trial in patients with colorectal cancer/polyposis syndromes.

Authors:  Carlos J Gallego; Caroline S Bennette; Patrick Heagerty; Bryan Comstock; Martha Horike-Pyne; Fuki Hisama; Laura M Amendola; Robin L Bennett; Michael O Dorschner; Peter Tarczy-Hornoch; William M Grady; S Malia Fullerton; Susan B Trinidad; Dean A Regier; Deborah A Nickerson; Wylie Burke; Donald L Patrick; Gail P Jarvik; David L Veenstra
Journal:  Contemp Clin Trials       Date:  2014-07-03       Impact factor: 2.226

10.  Partial loss of heterozygosity events at the mutated gene in tumors from MLH1/MSH2 large genomic rearrangement carriers.

Authors:  Katarina Zavodna; Tomas Krivulcik; Maria Gerykova Bujalkova; Tomas Slamka; David Martinicky; Denisa Ilencikova; Zdena Bartosova
Journal:  BMC Cancer       Date:  2009-11-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.